Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (Nasdaq: PSTV) has completed the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial for Rhenium NanoLiposome (RNL™) in recurrent glioblastoma patients. This cohort included increased drug volume to 8.8 milliliters and radiation dose to 22.3 millicuries. Eighteen patients have been treated to date. RNL has received Orphan Drug and Fast Track designations from the FDA, enhancing its development status. No dose-limiting toxicities were observed in interim data, indicating a favorable safety profile.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc Hedrick, M.D., President and CEO, will present a company overview at the 13th Annual LD Micro Main Event Conference on December 14 at 10:40 a.m. ET. Investors can attend via a live webcast available on the event’s homepage. Additionally, an archived recording will be accessible later on Plus Therapeutics' website. The company focuses on developing innovative treatments using nanotechnology targeting rare cancers, enhancing safety and efficacy for patients.
Plus Therapeutics (PSTV) has announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site for its ReSPECT™ Phase 1 clinical trial. This trial investigates the company's lead candidate, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The trial is supported by the National Cancer Institute. The sixth dose escalation cohort is currently underway, with enrollment expected to complete by the end of 2020. RNL has also received Orphan Drug and Fast Track designations from the FDA for glioblastoma treatment.
Plus Therapeutics (Nasdaq: PSTV) announced positive interim results from its ReSPECT™ Phase 1 trial of Rhenium NanoLiposome (RNL™) for treating recurrent glioblastoma (GBM). The trial demonstrated RNL's ability to deliver up to 15 times the radiation dose compared to standard external beam therapy, with no significant toxicity observed. All 15 patients in initial cohorts completed treatment, showing promising survival rates, particularly among those not previously treated with bevacizumab. The trial is advancing to its sixth dose escalation cohort, supported by FDA's Orphan Drug and Fast Track designations.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced participation in two virtual investor conferences. The first is the Virtual Fall Investor Summit on November 17, 2020, at 3:00 p.m. ET, followed by the A.G.P. Virtual Healthcare Symposium on November 19, 2020. Investors can arrange virtual 1x1 meetings with management. A live webcast of the first summit will be available on the company’s website. Plus Therapeutics focuses on innovative radiotherapeutic solutions for cancer treatment using a unique nanotechnology platform.
Plus Therapeutics (PSTV) will host a webinar on November 19, 2020, discussing interim data from the ReSPECT Phase 1 clinical trial for Rhenium NanoLiposome (RNL) in treating recurrent glioblastoma (GBM). The company recently received Orphan Drug and Fast Track designations from the FDA for RNL. The webinar will detail interim findings regarding safety, tolerability, and efficacy, presented by Dr. Andrew Brenner, a key figure in the trial. The ReSPECT trial aims to fully enroll by the end of 2020, highlighting a significant step in addressing the unmet medical needs in GBM treatment.
Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on nanoliposome-encapsulated radionuclides targeting various cancer types, including recurrent glioblastoma. The company is set to present at the virtual Fall Investor Summit scheduled for November 16-18, 2020. This summit will feature 75 companies and engage over 300 institutional and retail investors, providing a platform for fostering connections between smallcap and microcap firms and potential investors.
Plus Therapeutics (Nasdaq: PSTV) has announced the formation of a Scientific Advisory Board (SAB) to enhance its research and development efforts in the fields of neuro-oncology, preclinical drug development, and nanotechnology. The SAB will offer guidance for the advancement of the company’s innovative treatments, including its lead investigational drug, Rhenium NanoLiposomes (RNL™), aimed at treating recurrent glioblastoma. The board comprises notable experts, including Andrew Brenner, John McKew, and Vladimir P. Torchilin, whose collective experience is expected to strengthen Plus Therapeutics' drug development initiatives.
Plus Therapeutics announces the initiation of the sixth cohort in its NCI-supported ReSPECT™ Phase 1 clinical trial, targeting recurrent glioblastoma with Rhenium NanoLiposomes (RNL™). This progression follows a successful fifth cohort, backed by the Data and Safety Monitoring Board’s clearance. Cohort six will increase both the drug volume to 8.8 mL and radiation dose to 22.3 millicuries. This trial is part of Plus Therapeutics’ strategy to enhance treatment efficacy for glioblastoma, with interim data presentation scheduled for the 2020 SNO Annual Meeting in November.
Plus Therapeutics (PSTV) received FDA Orphan Drug and Fast Track designations for its glioblastoma treatment Rhenium NanoLiposome (RNL). The company reported a third-quarter net loss of $1.7 million or $(0.39) per share, compared to a net income of $0.5 million or $(0.03) per share in Q3 2019. The cash balance decreased to approximately $7.6 million from $17.6 million at the end of 2019. The ReSPECT Phase 1 trial continues with enrollment in the sixth cohort approved. A conference call is scheduled for October 22, 2020, to discuss these results.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
